PMC:7797241 / 34832-36043 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"291","span":{"begin":588,"end":593},"obj":"Gene"},{"id":"292","span":{"begin":76,"end":84},"obj":"Disease"},{"id":"293","span":{"begin":361,"end":369},"obj":"Disease"},{"id":"294","span":{"begin":502,"end":510},"obj":"Disease"},{"id":"295","span":{"begin":1070,"end":1078},"obj":"Disease"}],"attributes":[{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"Gene:163126"},{"id":"A292","pred":"tao:has_database_id","subj":"292","obj":"MESH:C000657245"},{"id":"A293","pred":"tao:has_database_id","subj":"293","obj":"MESH:C000657245"},{"id":"A294","pred":"tao:has_database_id","subj":"294","obj":"MESH:C000657245"},{"id":"A295","pred":"tao:has_database_id","subj":"295","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The ONS in England estimated that an average of 0.25% of the population had COVID-19 between 4 and 17 May 2020 (95% CI 0.16% to 0.38%),37 which is greater than the 0.10% (95% CrI 0.04% to 0.22%) we found with our model (on 11 May 2020), but with some overlap. In addition, the ONS estimated that 6.78% (95% CrI 5.21% to 8.64%) tested positive for antibodies to COVID-19 up to 24 May 2020 in England,38 and Public Health England estimated that approximately 4% (2%–6%) tested positive for antibodies to COVID-19 between 20 and 26 April 2020 in the SW.39 Compared with our model, 3.4% (95% CrI 2.5% to 5.0%) had recovered on 11 May 2020 (2 weeks later), demonstrating that our model estimates may be within sensible bounds, and further highlighting the need for more regional estimates of crucial epidemiological parameters and seroprevalence. We have assumed that individuals are not susceptible to reinfection within the model time frame; however, in future work it will be important to explore this assumption. It is not known what the long-term pattern of immunity to COVID-19 will be,40 and this will be key to understanding the future epidemiology in the absence of a vaccine or effective treatment options."}

{"project":"LitCovid-sentences","denotations":[{"id":"T206","span":{"begin":0,"end":259},"obj":"Sentence"},{"id":"T207","span":{"begin":260,"end":841},"obj":"Sentence"},{"id":"T208","span":{"begin":842,"end":1011},"obj":"Sentence"},{"id":"T209","span":{"begin":1012,"end":1211},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The ONS in England estimated that an average of 0.25% of the population had COVID-19 between 4 and 17 May 2020 (95% CI 0.16% to 0.38%),37 which is greater than the 0.10% (95% CrI 0.04% to 0.22%) we found with our model (on 11 May 2020), but with some overlap. In addition, the ONS estimated that 6.78% (95% CrI 5.21% to 8.64%) tested positive for antibodies to COVID-19 up to 24 May 2020 in England,38 and Public Health England estimated that approximately 4% (2%–6%) tested positive for antibodies to COVID-19 between 20 and 26 April 2020 in the SW.39 Compared with our model, 3.4% (95% CrI 2.5% to 5.0%) had recovered on 11 May 2020 (2 weeks later), demonstrating that our model estimates may be within sensible bounds, and further highlighting the need for more regional estimates of crucial epidemiological parameters and seroprevalence. We have assumed that individuals are not susceptible to reinfection within the model time frame; however, in future work it will be important to explore this assumption. It is not known what the long-term pattern of immunity to COVID-19 will be,40 and this will be key to understanding the future epidemiology in the absence of a vaccine or effective treatment options."}